DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Osteogenesis Imperfecta - Pipeline Review, H1 2017" report to their offering.
This report provides comprehensive information on the therapeutic development for Osteogenesis Imperfecta , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteogenesis Imperfecta and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Osteogenesis Imperfecta Overview
- Therapeutics Development
- Pipeline Products for Osteogenesis Imperfecta - Overview
- Pipeline Products for Osteogenesis Imperfecta - Comparative Analysis
- Osteogenesis Imperfecta - Therapeutics under Development by Companies
- Osteogenesis Imperfecta - Therapeutics under Investigation by Universities/Institutes
- Osteogenesis Imperfecta Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Osteogenesis Imperfecta - Products under Development by Companies
- Osteogenesis Imperfecta - Products under Investigation by Universities/Institutes
- Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
- Amgen Inc
- Bone Therapeutics SA
- Genzyme Corp
- Mereo Biopharma Group Plc
For more information about this report visit http://www.researchandmarkets.com/research/dpbphs/osteogenesis